BrainStorm Cell Therapeutics

What BrainStorm Cell Therapeutics does

BrainStorm Cell Therapeutics is a clinical-stage biotechnology company founded in 2000 and headquartered in New York, with research and development operations in Petach-Tikva, Israel through its wholly owned subsidiary Brainstorm Cell Therapeutics Ltd. The company is developing the NurOwn® technology platform, an autologous cellular therapy that uses a patient's own bone marrow-derived mesenchymal stem cells engineered to secrete elevated levels of neurotrophic factors (MSC-NTF cells). These cells are administered via intrathecal injection to deliver neurotrophic factors and immunomodulatory cytokines directly to sites of neurodegeneration, targeting diseases with significant unmet medical need such as amyotrophic lateral sclerosis (ALS), progressive multiple sclerosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, autism spectrum disorder, and acute respiratory distress syndrome.

The company's lead clinical program is a Phase 3b ENDURANCE trial (Study BCT-006-US) of NurOwn in ALS, conducted under a Special Protocol Assessment (SPA) agreement with the FDA—the first SPA ever granted for an ALS therapeutic candidate. This trial targets approximately 200 ALS patients earlier in their disease course (symptoms within 24 months, ALSFRS-R ≥35, slow vital capacity ≥65%) and is intended to support a future Biologics License Application (BLA). A Phase 2 open-label trial in progressive multiple sclerosis has been completed with support from the National MS Society, and the company maintains preclinical programs in Alzheimer's, Parkinson's, Huntington's, autism spectrum disorder, and peripheral nerve injury, plus an off-the-shelf exosome-based platform for ARDS. BrainStorm has secured Orphan Drug designation from both the FDA and EMA for NurOwn in ALS, Fast Track Designation, and holds an exclusive worldwide license to the platform from Ramot, Tel Aviv University's technology transfer company, with jointly held granted patents on neurotrophic factor-secreting cell compositions and methods.

BrainStorm is pre-revenue and has not yet commercialized any product. Its business model is contingent on securing FDA approval and subsequently commercializing NurOwn via enterprise field sales targeting US medical centers. The company has historically funded operations through a series of small, dilutive private placements and registered direct offerings, including $7.5 million raised in July 2023, $4.0 million in June 2024, and approximately $2.4 million across two February 2026 placements and a May 2026 placement. As of March 31, 2026, the company reported approximately $0.2 million in cash, $0.76 million in total assets against $11.76 million in total liabilities, and an $11 million stockholders' deficit—conditions that raise substantial going concern questions. BrainStorm trades on OTCQB under the ticker BCLI (previously listed on NASDAQ) with a market capitalization of approximately $10 million.

Name

BrainStorm Cell Therapeutics

Legal name

BrainStorm Cell Therapeutics Inc.

Website

https://brainstorm-cell.com

Company type

Public

Founded year

2000

Operating status

Operating

Headcount range

11–50 employees

Short description

BrainStorm Cell Therapeutics is a clinical-stage biotech developing NurOwn®, an autologous MSC-NTF cell therapy for ALS and other neurodegenerative diseases. The firm is preparing a Phase 3b ALS trial under an FDA Special Protocol Assessment and remains pre-revenue.

Ownership category

akta.pro rank

Product category

Cellular Therapeutics / Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell Therapy Developers (Autologous) (HLAAABAA)

akta.pro secondary industries

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Neurology/CNS Gene Therapies (HLAAACAH)

Keywords

• Autologous cell therapy
• Stem cell therapeutics
• Neurodegenerative disease treatment
• Clinical-stage biotechnology
• Cellular therapeutics platform

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Biologics License Application (BLA): Pre-revenue clinical-stage company. Revenue will be generated upon successful FDA approval and commercialization of NurOwn for ALS and other neurodegenerative diseases. No commercial products currently approved or generating sales.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

BrainStorm Cell Therapeutics is a clinical-stage biotechnology company developing NurOwn, a proprietary autologous cell therapy platform that produces MSC-NTF (mesenchymal stem cells secreting neurotrophic factors) cells from a patient's own bone marrow. The lead investigational product, NurOwn MSC-NTF cells, is being advanced for amyotrophic lateral sclerosis (ALS) and progressive multiple sclerosis, with additional preclinical programs targeting Alzheimer's, Parkinson's, Huntington's disease, autism spectrum disorder, and an off-the-shelf exosome program for ARDS.

Product overview

BrainStorm Cell Therapeutics is a clinical-stage biotechnology company developing the NurOwn® technology platform, a proprietary autologous cellular therapy that produces MSC-NTF (mesenchymal stem cells secreting neurotrophic factors) cells for treating highly debilitating neurodegenerative diseases. The platform represents a best-in-class approach using the patient's own bone marrow-derived stem cells. The lead product candidate NurOwn® MSC-NTF cells is being advanced through a Phase 3b trial for ALS under a Special Protocol Assessment with FDA, while the company has also completed a Phase 2 trial for progressive MS. Additional preclinical programs target Alzheimer's disease, Parkinson's disease, Huntington's disease, autism spectrum disorder, and peripheral nerve injury. A separate off-the-shelf exosome platform (NurOwn® MSC-NTF Cells Exosomes) is in development for ARDS.

Differentiator

Problem solved

Functional benefit

Brands

• NurOwn: Autologous MSC-NTF cell therapy platform for treating neurodegenerative diseases including ALS, MS, Alzheimer's, Parkinson's, Huntington's disease, and autism.
• MSC-NTF Cells

Products and services

• NurOwn Technology Platform
• NurOwn MSC-NTF Cells (ALS)
• Progressive MS Therapy Program
• NurOwn MSC-NTF Cells Exosomes (ARDS)

Quantifiable outcome

• 11% decline from baseline in neurofilament light (NfL) in NurOwn-treated Phase 3 participants vs. baseline unchanged in placebo group, indicating treatment-driven neuroprotection.
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Lunai Bioworks (BioSymetrics subsidiary)coreStrategic or Co-development Partner · 28 May 2026Strategic collaboration to jointly discover, validate, and advance novel therapeutic targets for neurological diseases, beginning with rare genetic epilepsies and Parkinson's disease. Supported by a grant from the LouLou Foundation. Combines BioSymetrics' AI-driven target discovery and in vivo zebrafish validation platform with BrainStorm's proprietary human-derived organoid systems.
• Ramot (Tel Aviv University Technology Transfer Company)coreTechnology or IntegrationExclusive worldwide licensing agreement for the NurOwn technology platform for clinical development and commercialization.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Clene Nanomedicine: Clinical-stage company developing CNM-Au8, a gold nanocatalyst therapy for ALS and other neurodegenerative diseases — comparable late-stage ALS pipeline and clinical-stage business model.
• Mesoblast: Commercial-stage MSC-based cell therapy company with remestemcel-L and rexlemestrocel platforms targeting inflammatory and degenerative diseases — directly comparable mesenchymal stem cell modality.
• Lineage Cell Therapeutics: Cell therapy developer with CNS-focused programs including OPC1 for spinal cord injury — analogous cell therapy platform targeting neurological indications.
• Athersys: Clinical-stage regenerative medicine company developing MultiStem cell therapy for stroke, ARDS, and trauma — directly comparable stem cell therapy platform with shared CNS and ARDS indications.
• Pluristem Therapeutics: Developer of placenta-derived cell therapies (PLX cells) with programs in ALS and other indications — comparable cell therapy modality and CNS focus.

Broad incumbents

• Cytokinetics: Late-stage ALS drug developer (reldesemtiv/ tirasemtiv programs) — directly competes for the same ALS patient population though using small-molecule muscle activators rather than cell therapy.
• Biogen: Large neuroscience company with tofersen approved for SOD1 ALS and broader neurodegenerative pipeline — broader incumbent in the same patient population.

Emerging players

• Helixmith (formerly ViroMed): Gene therapy developer (Engensis/VM202) targeting diabetic neuropathy and ALS — emerging player with overlapping neurological disease focus and CNS modality.
• Caladrius Biosciences: Cell therapy developer with CD34+ programs for ischemic conditions — comparable small-cap cell therapy developer navigating clinical and capital markets.
• Q Therapeutics: Preclinical/early clinical developer of neural cell therapies (Q-Cells) for ALS, MS, and spinal cord injury — emerging peer in the same CNS cell therapy space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/BrainStormCell
• YouTubevimeo.com/brainstormcell
• Facebookfacebook.com/BrainStormCell
• LinkedInlinkedin.com/company/brainstorm-cell-therapeutics

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries1 record

Funding overview

Funding rounds14 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BrainStorm Cell Therapeutics